Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03WQS
|
|||
| Former ID |
DCL000358
|
|||
| Drug Name |
BMS-582664
|
|||
| Synonyms |
Brivanib alaninate; BMS 582664; BMS582664; BMS-582664, Brivanib alaninate; Brivanib alaninate (INN/USAN); L-Alanine, (1R)-2-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo(2,1-f)(1,2,4)triazin-6-yl)oxy)-1-methylethyl ester
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 3 | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Bristol Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H24FN5O4
|
|||
| Canonical SMILES |
CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)OC(=O)C(C)N)C
|
|||
| InChI |
1S/C22H24FN5O4/c1-11-7-15-16(27-11)5-6-17(19(15)23)32-21-20-13(3)18(8-28(20)26-10-25-21)30-9-12(2)31-22(29)14(4)24/h5-8,10,12,14,27H,9,24H2,1-4H3/t12-,14+/m1/s1
|
|||
| InChIKey |
LTEJRLHKIYCEOX-OCCSQVGLSA-N
|
|||
| CAS Number |
CAS 649735-63-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16233765, 24458858, 42209717, 77346692, 92309407, 96025561, 99436997, 103577780, 124757026, 125163830, 126661322, 126680119, 126729215, 131480766, 135195809, 136340217, 136367326, 136920388, 142629726, 152258180, 160647016, 162011762, 162037460, 164837130, 174530181, 180423171, 184816560, 198987707, 223677760, 226799738, 248925490, 249565777, 252160520, 252438464, 252543406
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fibroblast growth factor receptor 3 (FGFR3) | Target Info | Inhibitor | [3] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| Endocytosis | ||||
| PI3K-Akt signaling pathway | ||||
| Signaling pathways regulating pluripotency of stem cells | ||||
| Regulation of actin cytoskeleton | ||||
| Pathways in cancer | ||||
| MicroRNAs in cancer | ||||
| Bladder cancer | ||||
| Central carbon metabolism in cancer | ||||
| Panther Pathway | FGF signaling pathway | |||
| Reactome | FGFR3 mutant receptor activation | |||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Endochondral Ossification | ||||
| Bladder Cancer | ||||
| Neural Crest Differentiation | ||||
| Signaling by FGFR | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8097). | |||
| REF 2 | ClinicalTrials.gov (NCT00908752) Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC. U.S. National Institutes of Health. | |||
| REF 3 | A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.